OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
August 07, 2020
The companies have agreements to supply its mRNA-based COVID-19 vaccine to Japan and Canada, pending regulatory approvals in those countries.
The company is working to ensure broad global access to its COVID-19 vaccine candidate, following approval from regulators.
Sanofi and GlaxoSmithKline have been selected to supply the US government and the European Union with millions of doses of their COVID-19 vaccine candidate.
August 06, 2020
The therapy, indicated for a rare form of B-cell non-Hodgkin’s lymphoma, was developed by Kite, a Gilead company, which will manufacture the therapy at its facility in El Segundo, CA.
August 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; only a handful have been approved. What are the bottlenecks?
July 29, 2020
Celltrion Healthcare has announced that the EC has granted marketing authorization for its subcutaneous formulation of Remsima (infliximab, CT-P13).
July 24, 2020
Patient advocates, research experts, and industry are calling for more user fee revenues to support CBER programs to advance innovative therapies.
July 21, 2020
Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?
July 09, 2020
FDA officials are moving to clarify standards and requirements for vetting and approving viable preventives.
July 01, 2020
While there currently is no molecular therapy targeted against the PAUFgene, Prestige believes its monoclonal antibody has the potential to benefit patients affected by PAUF-positive pancreatic cancer.